Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 19

1.

Dual-Function Polymeric HPMA Prodrugs for the Delivery of miRNA.

Peng ZH, Xie Y, Wang Y, Li J, Oupický D.

Mol Pharm. 2017 May 1;14(5):1395-1404. doi: 10.1021/acs.molpharmaceut.6b00999. Epub 2017 Jan 30.

PMID:
28134535
2.

Attenuation of chemokine receptor function and surface expression as an immunomodulatory strategy employed by human cytomegalovirus is linked to vGPCR US28.

Frank T, Reichel A, Larsen O, Stilp AC, Rosenkilde MM, Stamminger T, Ozawa T, Tschammer N.

Cell Commun Signal. 2016 Dec 12;14(1):31.

3.

Specificity for a CCR5 Inhibitor Is Conferred by a Single Amino Acid Residue: ROLE OF ILE198.

Lau G, Labrecque J, Metz M, Vaz R, Fricker SP.

J Biol Chem. 2015 Apr 24;290(17):11041-51. doi: 10.1074/jbc.M115.640169. Epub 2015 Mar 12.

4.

Insights into the mechanism of inhibition of CXCR4: identification of Piperidinylethanamine analogs as anti-HIV-1 inhibitors.

Das D, Maeda K, Hayashi Y, Gavande N, Desai DV, Chang SB, Ghosh AK, Mitsuya H.

Antimicrob Agents Chemother. 2015 Apr;59(4):1895-904. doi: 10.1128/AAC.04654-14. Epub 2015 Jan 12.

5.

Determination of the binding mode for the cyclopentapeptide CXCR4 antagonist FC131 using a dual approach of ligand modifications and receptor mutagenesis.

Thiele S, Mungalpara J, Steen A, Rosenkilde MM, Våbenø J.

Br J Pharmacol. 2014 Dec;171(23):5313-29. doi: 10.1111/bph.12842.

6.

Bridged cyclams as imaging agents for chemokine receptor 4 (CXCR4).

Woodard LE, De Silva RA, Behnam Azad B, Lisok A, Pullambhatla M, G Lesniak W, Mease RC, Pomper MG, Nimmagadda S.

Nucl Med Biol. 2014 Aug;41(7):552-61. doi: 10.1016/j.nucmedbio.2014.04.081. Epub 2014 Apr 21.

7.

Biased and g protein-independent signaling of chemokine receptors.

Steen A, Larsen O, Thiele S, Rosenkilde MM.

Front Immunol. 2014 Jun 23;5:277. doi: 10.3389/fimmu.2014.00277. eCollection 2014. Review.

8.

Discovery and computer aided potency optimization of a novel class of small molecule CXCR4 antagonists.

Vinader V, Ahmet DS, Ahmed MS, Patterson LH, Afarinkia K.

PLoS One. 2013 Oct 18;8(10):e78744. doi: 10.1371/journal.pone.0078744. eCollection 2013.

9.

Critical analysis of the successes and failures of homology models of G protein-coupled receptors.

Bhattacharya S, Lam AR, Li H, Balaraman G, Niesen MJ, Vaidehi N.

Proteins. 2013 May;81(5):729-39. doi: 10.1002/prot.24195. Epub 2013 Feb 14.

10.

Dual-function CXCR4 antagonist polyplexes to deliver gene therapy and inhibit cancer cell invasion.

Li J, Zhu Y, Hazeldine ST, Li C, Oupický D.

Angew Chem Int Ed Engl. 2012 Aug 27;51(35):8740-3. doi: 10.1002/anie.201203463. Epub 2012 Jul 31. No abstract available.

11.

Molecular requirements for inhibition of the chemokine receptor CCR8--probe-dependent allosteric interactions.

Rummel PC, Arfelt KN, Baumann L, Jenkins TJ, Thiele S, Lüttichau HR, Johnsen A, Pease J, Ghosh S, Kolbeck R, Rosenkilde MM.

Br J Pharmacol. 2012 Nov;167(6):1206-17. doi: 10.1111/j.1476-5381.2012.02076.x.

12.

Identification of anti-malarial compounds as novel antagonists to chemokine receptor CXCR4 in pancreatic cancer cells.

Kim J, Yip ML, Shen X, Li H, Hsin LY, Labarge S, Heinrich EL, Lee W, Lu J, Vaidehi N.

PLoS One. 2012;7(2):e31004. doi: 10.1371/journal.pone.0031004. Epub 2012 Feb 3.

13.

Preemptive dosing of plerixafor given to poor stem cell mobilizers on day 5 of G-CSF administration.

Horwitz ME, Chute JP, Gasparetto C, Long GD, McDonald C, Morris A, Rizzieri DA, Sullivan KM, Chao NJ.

Bone Marrow Transplant. 2012 Aug;47(8):1051-5. doi: 10.1038/bmt.2011.217. Epub 2011 Nov 14.

14.

Status of GPCR modeling and docking as reflected by community-wide GPCR Dock 2010 assessment.

Kufareva I, Rueda M, Katritch V, Stevens RC, Abagyan R; GPCR Dock 2010 participants.

Structure. 2011 Aug 10;19(8):1108-26. doi: 10.1016/j.str.2011.05.012.

15.

Pharmacological modulation of chemokine receptor function.

Scholten DJ, Canals M, Maussang D, Roumen L, Smit MJ, Wijtmans M, de Graaf C, Vischer HF, Leurs R.

Br J Pharmacol. 2012 Mar;165(6):1617-43. doi: 10.1111/j.1476-5381.2011.01551.x. Review.

16.

Novel compounds containing multiple guanide groups that bind the HIV coreceptor CXCR4.

Wilkinson RA, Pincus SH, Shepard JB, Walton SK, Bergin EP, Labib M, Teintze M.

Antimicrob Agents Chemother. 2011 Jan;55(1):255-63. doi: 10.1128/AAC.00709-10. Epub 2010 Oct 11.

17.

Distinctive properties of CXC chemokine receptor 4-expressing Cajal-Retzius cells versus GABAergic interneurons of the postnatal hippocampus.

Marchionni I, Takács VT, Nunzi MG, Mugnaini E, Miller RJ, Maccaferri G.

J Physiol. 2010 Aug 1;588(Pt 15):2859-78. doi: 10.1113/jphysiol.2010.190868. Epub 2010 Jun 14.

18.

The novel CXCR4 antagonist KRH-3955 is an orally bioavailable and extremely potent inhibitor of human immunodeficiency virus type 1 infection: comparative studies with AMD3100.

Murakami T, Kumakura S, Yamazaki T, Tanaka R, Hamatake M, Okuma K, Huang W, Toma J, Komano J, Yanaka M, Tanaka Y, Yamamoto N.

Antimicrob Agents Chemother. 2009 Jul;53(7):2940-8. doi: 10.1128/AAC.01727-08. Epub 2009 May 18.

19.

64Cu-AMD3100--a novel imaging agent for targeting chemokine receptor CXCR4.

Jacobson O, Weiss ID, Szajek L, Farber JM, Kiesewetter DO.

Bioorg Med Chem. 2009 Feb 15;17(4):1486-93. doi: 10.1016/j.bmc.2009.01.014. Epub 2009 Jan 15.

Supplemental Content

Support Center